Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Replimune Group (NASDAQ:REPL) released its quarterly earnings results on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09), Zacks reports.

Replimune Group Trading Up 2.2 %

Shares of NASDAQ:REPL traded up $0.28 during trading hours on Wednesday, hitting $13.13. 94,296 shares of the company’s stock traded hands, compared to its average volume of 755,579. The firm has a market capitalization of $898.35 million, a P/E ratio of -4.29 and a beta of 1.30. The business has a fifty day moving average price of $12.49 and a 200-day moving average price of $11.64. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Insider Transactions at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

REPL has been the topic of several recent research reports. Jefferies Financial Group upped their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright boosted their target price on Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and a consensus target price of $19.14.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.